Alex Manini, MD

In 2015, Dr. Manini received the Empire Clinical Research Investigator Program (ECRIP) from the New York, State Department of Health entitled Simulation Outcomes Research for ACLS.  He also received Promotion of Diversity in Health Related Research from the National Institute on Drug Abuse entitled, Opiate co-ingestion as a risk factor for acetaminophen hepatotoxicity.  Additionally, Dr. Manini received from the  NIH an Administrative Supplement from the National Institute on Drug Abuse (NIH/NIDA) entitled Assessment of novel serum biomarkers.

In 2014, Dr. Manini received a five-year Research Project Grant (R01) from the National Institute on Drug Abuse at the NIH. The award involves collaboration between Mount Sinai investigators in neuroscience, cardiology, epidemiology, emergency medicine, and medical toxicology, along with co-investigators from the NYU School of Medicine and the Toxicology Investigators’ Consortium, a national registry sponsored by the American College of Medical Toxicology. Clinical studies launched by the R01 will test a broad array of risk prediction instruments, laboratory biomarkers, and opioid receptor gene polymorphisms, with the goal to produce clinical tools to individualize prevention strategies for curtailing the national rise in drug overdose fatality.

In 2014, Dr. Manini was appointed Site PI of the NIDA National Early Warning System Network (iN3). The study is funded by an NIH High Priority Short Term Project (R56) from the National Institute on Drug Abuse. The goal of the study is to identify new episodes of emerging drug use nationally to advance drug surveillance from a reactive to anticipatory science.

In 2009, Dr. Manini received a Career Development Grant Award (K23) from the National Institute on Drug Abuse at the NIH. Mentored by David Vlahov, PhD and Lynne Richardson, MD, Dr. Manini studied clinical risk factors for adverse cardiovascular events in drug overdose emergencies.